Form 8-K · Current Report · Filed 2024-05-28
Kenvue Inc. Announces 2024 Annual Meeting Voting Results
Kenvue Inc. held its 2024 Annual Meeting of Shareholders on May 23, 2024, where shareholders elected all 11 director nominees, approved the compensation of named executive officers on a non-binding advisory basis, approved a one-year frequency for future advisory votes on executive compensation, and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2024.
- Filer
- Kenvue Inc. KVUE · NYSE
- Filed
- Accession
- 0001944048-24-000103
- CIK
- 0001944048
- Signal
- Medium impactConsumer Defensive
- Source
- Official filing on sec.gov ↗
Items reported
Submission of Matters to a Vote of Security Holders
Market reaction
Close before filing
$19.35
Next session
-2.5%
Since filing
-0.6%
Latest close
$19.24
What happened, not what will happen — closing prices around the filing date.
About Kenvue Inc.
Kenvue Inc. is a consumer healthcare and pharmaceutical company. It focuses on delivering a range of health-centric products, spanning hygiene, pain relief, and other wellness categories. With deep-rooted expertise in pharmaceuticals, Kenvue Inc. targets the health and wellness needs of individuals, providing both prescription and over-the-counter solutions. The company has established itself as a vital entity in the consumer health sector, significantly impacting community health standards and individual lives. Positioned in the pharmaceutical industry, Kenvue Inc. collaborates with healthcare providers to enhance its product reach and efficacy. Its broad portfolio includes well-known brands and formulations that are trusted globally by consumers seeking reliable health solutions. As a player in this sector, Kenvue Inc. contributes to the enhancement of public health, highlighting its prominence in both domestic and international markets.
Never miss another KVUE filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.